Irinotecan does not seem to increase toxicity but it improved response rates to 39%, added two to three months to disease-free survival, and prolonged overall survival by a little over two months.
Yes, irinotecan is primarily indicated for advanced and metastatic colon cancer.
Irinotecan targets actively dividing cells in your body. In cases of cancer, this is a good thing because it stops rapidly dividing cancer cells from growing. However, it can also affect other tissues of your body that have high turnover rate, including the bone marrow and epithelial lining of the intestine. Hence, irinotecan increases the risk of diarrhea and neutropenia.
The patients attitude, and what stage the cancer was found in.
Cancer patients who take astragalus during or after cancer treatments tend to recover more quickly from the ill effects of the treatment, and they generally have better survival rates.
If the entire visible tumor can be removed, about 25% of patients will be cured.
80% survival rate in adults, 75% in children
Patients who can have their entire tumor removed have the best chance for survival.
Persons who have cancerous spread to other distant places within the body (metastases) have stage IV cancer and the worst prognosis (potential for survival).
Only 3-17% of patients with anaplastic cancer survive for five years.
Eighty percent of patients with medullary thyroid cancer will live for at least 10 years after surgery.
The breast cancer survival rate varies greatly on the patient and their response to treatment. Breast cancer survival rates for early detection are 100%. Stage 2 breast cancer has a survival rate of 93 percent, the stage 3 survival rate is 72 percent, and the stage 4 survival rate is 22 percent.
The survival rate for patients with osseous metastasis varies significantly depending on several factors, including the primary cancer type, the extent of bone involvement, overall health of the patient, and the effectiveness of treatment. Generally, the prognosis can be poor, with median survival ranging from months to a few years. For instance, patients with metastatic breast cancer may have better outcomes compared to those with lung or prostate cancer. However, advancements in treatment continue to improve survival rates for many patients.